October 22, 2014
11 am to 12 pm EDT

Sponsored by

Webinar Description:

One of the challenges that bioanalytical labs face when running protein analysis is the reproducibility and sensitivity of the methods used. This is particularly true when one needs to utilize traditional Western blotting techniques. Trying to identify phosphorylated and non-phosphorylated protein isoforms and being able to quantitate those isoforms is becoming a must-have for most researchers in pharmacodynamics analysis, but difficult to accomplish when relying on traditional techniques.

Since its introduction in 2011, Simple Western has been applied to a myriad of applications where traditional Western was once considered the gold standard. Simple Western replaces the tedious and labor-intensive traditional Western with a gel-free, blot-free and hands-free approach. With highly reproducible and quantitative data in an automated platform, it delivers fully analyzed data in a matter of hours.

In this webinar, you will hear from two researchers, Dr. Afshin Safavi from BioAgilytix and Dr. Kristen McEachern from AstraZeneca. Dr. Safavi will summarize some uses of the Simple Western with case studies to demonstrate its application in biopharmaceutical and transgenic plant protein analysis. Following that, Dr. McEachern will discuss methods in developing a test to quantitatively measure changes post drug treatment for acute myeloid leukemia (AML). She will present how she uses the Simple Western cIEF assay (analysis of proteins by charge) to quantitatively measure changes in phosphorylation of a target protein in bone marrow and peripheral blood samples from patients enrolled in the Phase I trial of a novel drug. Dr. Patricia Piatti, Simple Western Product Manager, will close out the conversation with new product introductions – you won’t want to miss this!

Learning Objectives:

  • How the Simple Western platform integrates and automates all manual operations associated with Western blotting, from sample separation to quantitative data analysis
  • How to provide bioanalytical labs with reproducibility and sensitivity in their western blotting methods
  • How the Simple Western technology is applied to quantitative pharmacodynamics analysis in cancer research
  • How Simple Western provides tools to analyze proteins from 12 to 440 kDa, either by immunoassay or total protein analysis


Kristen A. McEachern, Ph.D.

Scientist, Oncology Translational Science
AstraZeneca R&D Boston

Kristen McEachern, Ph.D., is a Principal Scientist in the Oncology Translational Science group at AstraZeneca. In her role as a Translational Strategist, Kristen is responsible for devising and delivering the biomarker strategy for early clinical programs including biomarkers to demonstrate clinical proof of mechanism as well as patient selection biomarkers. Kristen also evaluates new biomarker detection platforms and oversees biomarker assay development for application in patient samples. Prior to working in Translational Science, Kristen worked in late stage Discovery, progressing both large and small molecule assets toward clinical development.

Afshin SafaviAfshin Safavi, Ph.D.

Founder and Chief Scientific Officer

Afshin Safavi, Ph.D., Afshin Safavi, Ph.D., Founder and Chief Scientific Officer, is a veteran biochemist with extensive experience in establishing and leading bioanalytical teams in support of the development of biological products in preclinical and clinical-trial laboratories. Prior to founding BioAgilytix Labs, he was the Director of Ligand Binding and Immunoassay at AAIPharma. At Grifols, he led the Preclinical and Clinical Assay Development team, building on his experience as a senior scientist at Nobex Corporation, GSK and BioVeris. Dr. Safavi is considered an expert in the area of immunoassay with a wide working knowledge of various platforms. He obtained his B.S. in Biochemistry from UCLA, his Ph.D. in Biochemistry from University of Kentucky Medical School, and completed a two-year postdoctoral assignment at the Emory University, Department of Pathology.

Cost: No cost!